Atenolol
As of the edition of 20 October 2026, Atenolol is a small molecule: marketed, first approved in 1976 (CH); acts on ADRB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Tenormin
- First approved
- 19 August 1976 (CH)
- Approvals on record
- 9 in 4 regions
- Holder of the most recent approval
- Twi Pharmaceuticals; 5 holders in all
- Registered trials
- 55, 8 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Inherited and neonatal; Hormones; Bones, joints and muscles; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | P08588 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 15 | 9 | 1 | 3 |
| Phase 1 | 7 | 5 | 0 | 1 |
| Phase 2 | 5 | 2 | 0 | 2 |
| Phase 3 | 13 | 9 | 1 | 1 |
| Phase 4 | 15 | 12 | 0 | 1 |
| All trials | 55 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Later holder and Earlier holder | 1989 to now |
| Twi Pharmaceuticals | Acquired holder | 2023 to now |